Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells

• Published in: Cell death & disease 2012-01, Vol.3 (1), p.e262-e262
• Main Authors: Kharaziha, P, Rodriguez, P, Li, Q, Rundqvist, H, Björklund, A-C, Augsten, M, Ullén, A, Egevad, L, Wiklund, P, Nilsson, S, Kroemer, G, Grander, D, Panaretakis, T
• Format: Article
• Language: English
• Subjects: 631/80/82; 631/92/609; 692/699/67/1059; 692/699/67/589/466; Antibodies; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apoptosis - drug effects; Benzenesulfonates - pharmacology; Biochemistry; Biomedical and Life Sciences; Carcinoma; Cell Biology; Cell Culture; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm - drug effects; Fibroblasts - cytology; Fibroblasts - metabolism; Gene Expression Regulation, Neoplastic - drug effects; Humans; Immunology; Life Sciences; Male; Medicin och hälsovetenskap; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide - analogs & derivatives; Original; original-article; Phenylurea Compounds; Phosphorylation - drug effects; Primary Cell Culture; Prostate; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Protein Kinase Inhibitors - pharmacology; Proto-Oncogene Proteins c-akt - genetics; Proto-Oncogene Proteins c-akt - metabolism; Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors; Proto-Oncogene Proteins c-bcl-2 - genetics; Proto-Oncogene Proteins c-bcl-2 - metabolism; Proto-Oncogene Proteins pp60(c-src) - genetics; Proto-Oncogene Proteins pp60(c-src) - metabolism; Pyridines - pharmacology; Signal Transduction - drug effects; Signal Transduction - genetics
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/cddis.2012.1

Sorafenib, a multi-tyrosine kinase inhibitor, kills more effectively the non-metastatic prostate cancer cell line 22Rv1 than the highly metastatic prostate cancer cell line PC3. In 22Rv1 cells, constitutively active STAT3 and ERK are targeted by sorafenib, contrasting with PC3 cells, in which these kinases are not active. Notably, overexpression of a constitutively active MEK construct in 22Rv1 cells stimulates the sustained phosphorylation of Bad and protects from sorafenib-induced cell death. In PC3 cells, Src and AKT are constitutively activated and targeted by sorafenib, leading to an increase in Bim protein levels. Overexpression of constitutively active AKT or knockdown of Bim protects PC3 cells from sorafenib-induced killing. In both PC3 and 22Rv1 cells, Mcl-1 depletion is required for the induction of cell death by sorafenib as transient overexpression of Mcl-1 is protective. Interestingly, co-culturing of primary cancer-associated fibroblasts (CAFs) with 22Rv1 or PC3 cells protected the cancer cells from sorafenib-induced cell death, and this protection was largely overcome by co-administration of the Bcl-2 antagonist, ABT737. In summary, the differential tyrosine kinase profile of prostate cancer cells defines the cytotoxic efficacy of sorafenib and this profile is modulated by CAFs to promote resistance. The combination of sorafenib with Bcl-2 antagonists, such as ABT737, may constitute a promising therapeutic strategy against prostate cancer.